Unigene to Present at IBC's 4th Annual AsiaTIDES Oligonucleotide and Peptide Conference

^{Published on 2012-02-27 06:10:45 - Market Wire}
 

Unigene to Present at IBC's 4th Annual AsiaTIDES Oligonucleotide and Peptide Conference -- BOONTON, N.J., Feb. 27, 2012 /PRNewswire/ --

Plenary Keynote by Unigene's Dr. Nozer Mehta to Highlight Recent Advances in the Delivery of Peptide Pharmaceuticals

BOONTON, N.J., Feb. 27, 2012 /PRNewswire/ -- Unigene Laboratories, Inc. (OTCBB: UGNE), a leader in the design, delivery, manufacture and development of peptide-based therapeutics, today announced the Company's Vice President of Research and Development, Nozer Mehta, Ph.D., will be presenting at IBC's 4th Annual AsiaTIDES Oligonucleotide and Peptide® Conference being held at the Sheraton Miyako Hotel in Tokyo, Japan.

The TIDES Oligonucleotide and Peptide Conferences are the premier forums focused on oligonucleotide and peptide-based therapeutics, serving as an annual gathering point for the leading companies, academics and researchers in the field.  As a key industry opinion and thought leader, Dr. Mehta will address the conference attendees on topics of critical importance to the growth of peptide therapeutics.

Recent Advances in Routes of Delivery for Peptide Pharmaceuticals

Plenary keynote presentation

• Given by: Nozer Mehta, Ph.D., Vice President of Research and Development for Unigene
• Date & Time: Tuesday, February 28, at 4:30pm JST (Tuesday, February 28, at 2:30am EST)
• Focus: Peptides in advanced stages of clinical development with oral or transdermal technologies

Clinical Development of a Solid Dosage Oral Formulation for the 32 Amino Acid Peptide Salmon Calcitonin

• Given by: Nozer Mehta, Ph.D., Vice President of Research and Development for Unigene
• Date & Time: Thursday, March 1, at 12:00pm JST (Wednesday, February 29, at 10:00pm EST)
• Focus: Advantages of Unigene's oral delivery technology demonstrated in a Phase 3 clinical study for salmon calcitonin, including an improved variability profile and limited food effects on the biological activity of the peptide

"I welcome the opportunity to provide the attendees of AsiaTIDES with a comprehensive review of recent advancements in the delivery of peptides, most notably Unigene's validated and most clinically advanced oral peptide delivery technology platform, as well as the company's late-stage and feasibility oral peptide programs developed via our Peptelligence™ platform," said Dr. Mehta. "Advances in the delivery of peptide therapeutics, particularly oral peptide technologies, have the opportunity to redefine the treatment regimen and market for numerous debilitating, chronic conditions.  Given this opportunity, the pharmaceutical industry is directing increasing attention and resources to companies and institutions that are developing next-generation peptide compounds, making a conference like AsiaTIDES an extremely valuable scientific and business development event."

About Unigene Laboratories, Inc.:

Unigene Laboratories, Inc. is a leader in the design, delivery, manufacture and development of peptide-based therapeutics. The Company is building a robust portfolio of proprietary partnerships in this expanding drug class based on its Peptelligence™ platform. Peptelligence encompasses extensive intellectual property covering delivery and manufacturing technologies, unsurpassed research and development expertise, and proprietary know-how representing a genuine distinctive competence. Core Peptelligence assets include proprietary oral and nasal peptide delivery technologies, and proprietary, high-yield, scalable and reproducible E. coli-based manufacturing technologies.

Investor Contact:
Unigene Laboratories, Inc.
Jenene Thomas
VP, Investor Relations and Business Administration
973-265-1107
[ jthomas@unigene.com ]

Media Contact:
Tiberend Strategic Advisors, Inc.
Jason Rando / Andrew Mielach
212-827-0020
[ jrando@tiberend.com ] / [ amielach@tiberend.com ]

SOURCE Unigene Laboratories, Inc.